Omalizumab Retreatment of Patients swith Chronic Idopathic Urticaria/Spontaneous Urticaria (CIU/CSU) Following Return of Symptoms: Primary Results of the OPTIMA Study

Main Article Content

Gordon Sussman
Jacques Hebert
Wayne Gulliver
Charles Lynde
William H Yang
Olivier Chambenoit
Antonio Vieira
Frederica De Takacsy
Lenka Rihakova

Keywords

urticaria, omalizumab, chronic urticaria, biologic therapy

Abstract

Abstract Not Available

Article Sidebar

Poster PDF
Published
Oct 27, 2017
DOI https://doi.org/10.25251/skin.1.supp.126

Article Details

How to Cite
Sussman, G., Hebert, J., Gulliver, W., Lynde, C., Yang, W. H., Chambenoit, O., Vieira, A., De Takacsy, F., & Rihakova, L. (2017). Omalizumab Retreatment of Patients swith Chronic Idopathic Urticaria/Spontaneous Urticaria (CIU/CSU) Following Return of Symptoms: Primary Results of the OPTIMA Study. SKIN The Journal of Cutaneous Medicine, 1(3.1), s127. https://doi.org/10.25251/skin.1.supp.126
Issue
Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Section
Urticaria
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 > >>